Sigma Healthcare Valuation

Is SIGG.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SIGG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SIGG.F ($0.92) is trading below our estimate of fair value ($5.06)

Significantly Below Fair Value: SIGG.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SIGG.F?

Key metric: As SIGG.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SIGG.F. This is calculated by dividing SIGG.F's market cap by their current revenue.
What is SIGG.F's PS Ratio?
PS Ratio	1.2x
Sales	AU$3.48b
Market Cap	AU$4.21b

SIGG.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	140.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SIGG.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SIGG.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.4x
PDCO Patterson Companies	0.3x	3.0%	US$1.9b
AHCO AdaptHealth	0.4x	3.4%	US$1.3b
OMI Owens & Minor	0.1x	4.2%	US$1.1b
HSIC Henry Schein	0.8x	4.5%	US$9.6b
SIGG.F Sigma Healthcare	1.2x	21.5%	US$4.2b

Price-To-Sales vs Peers: SIGG.F is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.4x).

Price to Sales Ratio vs Industry

How does SIGG.F's PS Ratio compare vs other companies in the US Healthcare Industry?

36 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$78.29b
CVS CVS Health	0.2x	4.5%	US$75.61b
COR Cencora	0.2x	6.5%	US$47.87b
CNC Centene	0.2x	5.5%	US$31.01b

36 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SIGG.F is expensive based on its Price-To-Sales Ratio (1.2x) compared to the US Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is SIGG.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SIGG.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SIGG.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$89.53

12.7%

29.8%

Elevance Health

US$94.5b

Operates as a health benefits company in the United States.

ELV

US$401.96

2.0%

-15.5%

Centene

US$31.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

3.8%

-17.8%